ArticleFrontiers in immunology2026
Identification of a prognostic signature based on ammonia metabolism-related genes in clear cell renal cell carcinoma: an integrated analysis of bulk and single-cell transcriptomics.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is an angiogenic tumor originating from proximal tubule epithelial cells. Ammonia induced cell death is closely associated with carcinogenesis, but its potential mechanism in ccRCC remains unclear and requires further investigation. Methods: The transcriptomic data of ccRCC and the genes related to ammonia induced cell death were retrieved from public resources. Candidate genes were ascertained by taking the common part of the Differentially Expressed Genes (DEGs) and the Ammonia death-related genes (ADRGs). Prognostic genes were filtered using machine learning and a prognostic model was established. ccRCC patients were segmented into a high-risk group (HRG) and a low-risk group (LRG) in accordance with the risk score values. Functional enrichment, immune infiltration analysis, somatic mutation and Reverse transcription quantitative PCR (RT-qPCR) were also executed. Key cells were identified at the single-cell level, and analyses including cell communication and pseudo-temporal analysis were conducted. Results: The risk model was constructed from 6 prognostic genes (RGS20, ADA, AICDA, SLC12A5, RUFY4 and CDK5RAP3). RGS20, ADA, AICDA, SLC12A5, RUFY4 and CDK5RAP3 were significantly upregulated in ccRCC group, and the RT - qPCR analysis results were consistent (p < 0.05). Enrichment analysis suggested that HRG and LRG were linked to pathways, such as "olfactory transduction" signaling pathway (p < 0.05). Sixteen immune cells with differential abundance between HRG and LRG were identified, such as activated B cells. The most frequent type of mutation between HRG and LRG was missense mutation. Malignant cells (MCs) were identified as the key cells. Moreover, frequent interactions between MCs and T cells were observed in ccRCC, and 6 prognostic genes were involved in the regulation of MCs' expression. Conclusion: This study identified 6 prognostic genes for ccRCC, MCs were identified as the key cells. We explored potential mechanisms and prognostic associations in ccRCC, providing new insights for potential therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.